Monosialotetrahexosylganglioside 2 (GM2) (GM2)

Monosialotetrahexosylganglioside 2 (GM2) is a sialic acid-containing glycosphingolipid, or ganglioside, primarily located in the outer leaflet of the plasma membrane (PubChem CID 10857447). In normal physiology, it is found at low levels in various tissues and is involved in critical processes such as cell-cell recognition, adhesion, and signal transduction, particularly within the central nervous system (NIH, 2023). GM2 is highly overexpressed in several neuroectoderm-derived tumors, including melanoma, neuroblastoma, and certain sarcomas, which makes it a significant tumor-associated antigen for targeted immunotherapy (Livingston, 1995, 'GM2 ganglioside as a target for cancer immunotherapy'). Conversely, the pathological accumulation of GM2 in lysosomes, caused by a deficiency in the enzyme beta-hexosaminidase A or its activator protein, leads to severe neurodegenerative conditions known as GM2 gangliosidoses, such as Tay-Sachs and Sandhoff diseases (StatPearls, 2023, 'Tay-Sachs Disease'). Therapeutic strategies targeting GM2 include active immunization with vaccines like GM2-KLH to elicit an immune response against cancer cells and passive immunotherapy using monoclonal antibodies (ClinicalTrials.gov, NCT00003142). Despite its potential, targeting GM2 poses challenges such as the risk of autoimmune cross-reactivity with normal neural tissues and the inherently low immunogenicity of carbohydrate antigens.

Other names

GM2 gangliosideGanglioside GM2GalNAc-GD1aII3Neu5Ac-Gg3CerMonosialoganglioside GM2

Active immunization to induce endogenous anti-GM2 antibodies (IgM and IgG) that mediate complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) against tumor cells expressing GM2.